BazEkon - Biblioteka Główna Uniwersytetu Ekonomicznego w Krakowie

BazEkon home page

Meny główne

Różalska Anna (Institute of Mother and Child, Warsaw University of Technology Business School, Poland), Czech Marcin (Warsaw University of Technology Business School, Poland)
Drug Policy as an Integral Part of State Health Policy - International Examples
Journal of Health Policy and Outcomes Research, 2017, nr 1, s. 4-13, rys., tab., bibliogr. 32 poz.
Słowa kluczowe
Zwalczanie narkomanii, Polityka zdrowotna
Combating drug addiction, Health care policy
Medicines policy plays a major role in protecting, maintaining and restoring people's health and is an integral part of state health policy. It embraces brand and generic drugs, biologics, vaccines and natural health products. Drug policy ensures an access to safe and effective medicines while reducing patient participation in treatment costs. Medicine policy includes among others, patent law, licensing, prescribing, pricing, reimbursement, formulary management, eligibility, pharmacy, funding of research in the life sciences services[1] The national pharmaceuticals policy is the one based on drug use where patients receive medications according to their clinical needs, in the individual required doses, in the right time, at the lowest possible cost [3]. In this article national medicine policies in Australia, United Kingdom, Sri Lanka, South Africa and Poland were presented from the viewpoints of drugs' spending, regulations and practice. The general policy framework addresses the inherent tensions within the objectives of attaining affordable access to medicines, while maintaining a viable pharmaceutical industry, and achieving quality medicines and healthcare systems. In Poland development of medicine policy is under creation.(original abstract)
Pełny tekst
  1. Kanji N, Hardon A, Harnmeijer JW, Mamdani M, Walt G: Drugs Policy in Developing Countries. 1992, London: Zed Books, 136
  2. Another Development in Pharmaceuticals. Development Dialogue, Volume 2. 1985, Uppsala: Dag Hammarskjold Foundation, publications/development-dialogue/another-development-in-pharmaceuticals/_16/08/2017
  4. WHO: Equitable access to essential medicines: a framework for collective action. 2004, Geneva: World Health Organization,
  5. Cameron A, Ewen M, Ross-Degnan D, Ball D, Laing R: Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. Lancet. 2009, 373 (9659): 240-9. 10
  6. Dukes MNG HRFM, de Joncheere CP, Rietveld AH: Prices, affordability and cost containment. 2003, Geneva: Drugs and Money, World Health Organization; 2003, 7
  7. United Nations: Delivering on the Global Partnership for Achieving the Millennium Development Goals, in MDG Gap Task Force Report. 2008, New York: United Nations
  8. Calabrese LH: Changing patterns of morbidity and mortality in HIV disease. Cleveland Clinical Journal of Medicine. 2001, 68 (2): 109-110
  9. WHO: How to develop and implement a national drug policy, in WHO Policy Perspectives on Medicines. 2003, Geneva: World Health Organization, Available at: Js4869e/ 18/08/2017
  10. WHO: Guidelines for developing national drug policies. 1988, Geneva: World Health Organization, available at: 18/08/2017
  11. The Global Use of Medicines: Outlook through 2017. Report by the IMS Institute for Healthcare Informatics
  12. Journal of Pharmaceutical Policy and Practice20136:5. "National medicines policies - a review of the evolution and development processes"
  13. policies 14/.08/.2017
  14. . 15.08.2017 Am I entitled to NHS treatment when I visit England?". 21/08/2017 [14]
  15. 27/08/2017
  16. WHO: How to develop and implement a national drug policy, in WHO Policy Perspectives on Medicines. 2003, Geneva: World Health Organization
  17. 27/08/2017
  18. pulsu-medycyny -i- pulsu-farmacji -na-temat-polityki-lekowej-panstwa/ 26/07/2017
  19.,168800,6.html 24/08/2017
  20. 26/08/2017
  21. WHO: Country pharmaceutical situations; Fact Book on WHO Level 1 indicators 2007. 2009, Geneva: World Health
  22. WHO: The World Medicines Situation. 2004, Geneva: World Health Organization, available at: http:// 21/08/2017
  23. Hamrell S, Nordberg O: A Search for Balance: Pharmaceuticals in Sri Lanka. Making National Drug Policies a Development Priority: A Strategy Paper and Six Country Stories. Development dialogue. Edited by: Weerasuriya K. 1995, The Journal of The Dag Hammarskjöld Foundation, 1-available at: http:// 22/08/2017
  24. Vitry A: LJ, Mansfield PR Is Australia's national medicines policy failing? The case of COX-2 inhibitors. Int J Health Serv. 2007, 37 (4): 735-44. 10.2190/HS.37.4.
  25. Hamrell S, Nordberg O: Australian National Drug Policies: Facilitating or Fragmenting Health. Australian National Drug Policies: Facilitating or Fragmenting Health. Edited by: Murray M. 1995, The Journal of The Dag Hammarskjöld Foundation, available at: Js19177en/ 23/08/2017
  26. Department of Health and Ageing, Quality Use Of Medicines: A Decade Of Research, Development and Service Activity 1991 - 2001. 2001, Australian Government, Available at: internet/main/publishing.nsf/Content/nmp-pdf-qumresearch-cnt.htm 23/08/2017
  27. World Health Organization: Developments in the South African Drug Action Programme. 2001, Available at: Js2230e/2.html#Js2230e.2.1 25/08/2017
  28. Department of Health: National Drug Policy for South Africa. 1996, Available at: medicinedocs/en/m/abstract/Js17744en/ 23/08/2017
  29. Walley T, Earl-Slater A, Haycox A, Bagust A: An integrated national pharmaceutical policy for the United Kingdom. BMJ. 2000, 321 (7275): 1523-6.
  30. Js4869e/14/08/2017
  31. 21/08/2017
  32. Jahnz-Różyk K, Kawalec P, Malinowski K, Czok K, Drug Policy in Poland, Value In Health Regional Issues 13 C, 2017, 23-26
Cytowane przez
Udostępnij na Facebooku Udostępnij na Twitterze Udostępnij na Google+ Udostępnij na Pinterest Udostępnij na LinkedIn Wyślij znajomemu